User:Sonia Lee/Notebook/Gastric Cancer Immune Trials

From OpenWetWare

Jump to: navigation, search

Search this Project

Customize your entry pages

A brief overview of adverse events in immune-based gastric cancer trials

This was a request for a book chapter I decided not to submit. Codes covers the discussion on published evidence.

Supplementary codes (literature glean)

  • Searched strategies conducted 18th September 2015:

MEDLINE via OVID search strategy

1. Gastric Fundus/ or Vagotomy, Proximal Gastric/ or Gastric Bypass/ or Gastric Absorption/ or Gastric Outlet Obstruction/ or gastric.mp or "Esophageal and Gastric Varices"/ or Gastric Stump/ or Chief Cells, Gastric/ or Gastric Mucosa/ or Gastric Juice/ or Gastric Balloon/ or Gastric Acid/ or Gastric Emptying/ or Gastric Inhibitory Polypeptide/ or Gastric Mucins/ or "Respiratory Aspiration of Gastric Contents"/ or Gastric Lavage/ or Gastric Dilatation/ or Gastric Acidity Determination/ or Gastric Fistula/ or Parietal Cells, Gastric Antral Vascular Ectasia/
2. solid$.mp or Response Evaluation Criteria in Solid Tumors/
3. immunotherapy.mp. or Immunotherapy, Active/ or Immunotherapy/ or Sublingual Immunotherapy/ or Immunotherapy, Adoptive/
4. immun$.mp.
5. VEGF.mp or Vascular Endothelial Growth Factor/
6. Calcitonin Receptor-Like Protein/ or Nuclear Receptor Subfamily 4, Group A, Member 1/ or Interleukin-21 Receptor alpha Subunit/ or Toll-like Receptor 3/ or Genes, T-cell Receptor beta/ or Nuclear Receptor Coactivator 2/ or Receptor-Related Protein-5/ or alpha7 Nicotinic Acetylcholine Receptor/ or G-Protein-Coupled Receptor Kinase 1/ or Interleukin-13 Receptor alpha2 Subunit/ or Receptor, Parathyroid Hormone, Type 2/ or Serotonin 5-HT3 Receptor Agonists/ or Receptor, Fibroblast Growth Factor, Type 2/ or G-Protein-Coupled Receptor Kinase 3/ or Receptor, Melatonin, MT2/ or Receptor, Angiotensin, Type 1/ or Interleukin-2 Receptor beta Subunit/ or Receptor, Endothelin B/ or Bradykinin Receptor Antagonists/ or Cannabinoid Receptor Modulators/ or Adrenergic beta-1 Receptor Antagonists/ or Receptor-Like Protein Tyrosine Phosphatases, Class 2/ or Interleukin-5 Receptor alpha Subunit/ or Bradykinin B1 Receptor Antagonists/ or Receptor, Galanin, Type 2/ or NK Cell Lectin-Like Receptor Subfamily K/ or Receptor, Muscarinic M5/ or G-Protein-Coupled Receptor Kinase 4/ or Receptor-Like Protein Tyrosine Phasphatases, Class 5/ or Receptor Activity-Modifying Protein 1/ or Adrenergic beta-3 Receptor Activity-Modifying Protein 1/ or Adrenergic beta-3 Receptor Antagonists/ or Genes, T-Cell Receptor gamma/ or Low Density Lipoprotein Receptor-Related Protein-2/ or Interleukin 1 Receptor Antagonist Protein/ or GABA-A Receptor Antagonists/ or Gene Rearrangement, delta-Chain T-Cell Antigen Receptor/ or Receptor, Serotonin, 5-HT2B/ or Receptor, Galanin, Type 1/ or Protein Tyrosine Phosphatase, Non- Receptor Type 22/ or Nuclear Receptor Subfamily 4, Group A, Member 3/ or Toll-Like Receptor 7/ or Toll-Like Receptor 1/ or Receptor Protein-Tyrosine Kinases/ or Retinoid X Receptor alpha/ or Receptor, Melancortin, Type 4/ or Receptor, IGF Type 2/ or Receptor, Cannabinoid, CB2/ or Receptor, EphB1/ or Protein Tyrosine Phosphatase, Non-Receptor Type 11/ or Adrenergic beta-3 Receptor Agonists/ or Purinergic P1 Receptor Antagonists/ or Estrogen Receptor alpha/ or Receptor, EphA3/ or Aryl Hydrocarbon Receptor Nuclear Translocator/ or Vascular Endothelial Growth Factor Receptor-1/ or Protein Tyrosine Phosphatase, Non-Receptor Type 3/ or Nuclear Receptor Subfamily 1, Group F, Member 3/ or Lymphtoxin beta Receptor/ or Olfactory Receptor Neurons/ or Receptor, EphA6/ or Receptor, Platelet-Derived Growth Factor alpha/ or Receptor Activity-Modifying Protein 2/ or Adenosine A1 Receptor Agonists/ or Antidiuretic Hormone Receptor Antagonists/ or Interleukin Receptor Common gamma Subunit/ or Receptor, Adenosine A2B/ or Receptor, Adenosine A3/ or Endothelin B Receptor/ or Protein Tyrosine Phosphatases, Class 8/ or Estrogen Receptor beta/ or T-Cell Antigen Receptor Specificity/ or Oncostatin M Receptor beta Subunit/ or Receptor-CD3 Complex, Antigen, T-Cell/ or Receptor, Cholecystokinin B/ or Receptor, Galanin, Type 3/ or Androgen Receptor Antagonists/ or Nuclear Receptor Subfamily 2, Group C, Member 1/ or Dopamine D2 Receptor Antagonists/ or Bacterial Transferrin Receptor Complex/ or TNF Receptor-Associated Factor 6/ or Receptor Aggregation/ or Receptor, ErbB-2/ or Interleukin-7 Receptor alpha Subunit/ or Angiotensin II Type 2 Receptor Blockers/ or Neurokinin-1 Receptor Antagonists/ or Receptor, PAR-2/ or Receptor, TIE-1/ or Purinergic P2Y Receptor Antagonists/ or Purinergic P2X Receptor Agonists/ or Vascular Endothelial Growth Factor Receptor-3/ or Interleukin-10 Receptor alpha Subunit/ or Natural Cytoxicity Triggering Receptor 1/ or Toll-like Receptor 2/ or Receptor, Adenosine A1/ or Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor/ or Receptor, Fibroblast Growth Factor, Type 5/ or Receptor, Insulin/ or Serotonin 5-HT4 Receptor Agonists/ or Protein Tyrosine Phosphatase, Non-Receptor Type 2/ or Interleukin-12 Receptor beta 1 Subunit/ or Protein Tyrosine Phosphatase, Non-Receptor beta Subunit/ or Protein Tyrosine Phosphatase, Non-Receptor Type 13/ or G-Protein-Coupled Receptor Kinases/ or "Tumor Necrosis Factor Receptor-Associated Peptides and Proteins"/ or Interleukin-18 Receptor alpha Subunit/ or Receptor, trkC/ or Receptor-Interacting Protein Serine-Threonine Kinase 2/ or Receptor$.mp. or Receptor, Bradykinin B1/ or Amylin Receptor Agonists/ or Adenosine A2 Receptor Agonists/ or Receptor, EphB3/ or Interleukin-12 Receptor beta 2 Subunit/ or NK Cell Lecin-Like Receptor Subfamily A/ or Purinergic P2 Receptor Antagonists/ or Receptor, Notch1/ or TNF Receptor-Associated Factor 2/ or Genes, T-Cell Receptor/ or NK Cell Lectin-Like Receptor Subfamily C/ or Receptor, Ciliary Neurotrophic Factor/ or Receptor, ErbB-3/ or Receptor, Muscarinic M3/ or Receptor, EphB4/ or Receptor, Muscarinic M2/ or Toll-like Receptor 9/ or Serotonin 5-HT4 Receptor Antagonists/ or Interleukin-10 Receptor beta Subunit/ or Nuclear Receptor Subfamily 1, Group D, Member 1/ or Receptor-Like Protein Tyrosine Phosphatases, Class 7/ or Nuclear Receptor Subfamily 2, Group C, Member 2/ or Receptor, Serotonin, 5-HT1B/ or Retinoid X Receptor gamma/ or Selective Estrogen Receptor Modulators/ or Toll-Like Receptor 6/ or Receptor, EphA1/ or Receptor-Like Protein Tyrosine Phosphatases, Class 3/ or Receptor, Melanocortin, Type 2/ or Serotonin 5-HT1 Receptor Antagonists/ or Nuclear Receptor Coactivator 1/ or Receptor, Cholecystokinin A/ or Cannabinoid Receptor Agonists/ or GABA-B Receptor Agonists/ or Adrenergic alpha-1 Receptor Antagonists/ or Interleukin-11 Receptor alpha Subunit/ or B-cell Activation Factor Receptor/ or Receptor, Nerve Growth Factor/ or Leukemia Inhibitory Factor Receptor alpha Subunit/ or Genes, T-Cell Receptor delta/ or Receptor, EphA4/ or Smad Proteins, Receptor-Regulated/ or Serotonin 5-HT1 Receptor Agonists/ or Receptor, EphA7/ or Natural Cytotoxicity Triggering Receptor 3/ or Toll-like Receptor 4/ or Interleukin-4 Receptor alpha Subunit/ or Receptor, Parathyroid Hormone, Type 1/ or Adrenergic beta-1 Recetor Agonists/ or Receptor, Muscarinic M4/ or Protein Tyrosine Phosphatase, Non-Receptor Type 6/ or Receptor-Like Protein Tyrosine Phosphatases/ or Serotonin Receptor Agaonists/ or Receptor, Cannabinoid, CB1/ or Endothelin Receptor Antagonists/ or Programmed Cell Death 1 Receptor/ or Nuclear Receptor Subfamily 1, Group F, Member 2/ or Purinergic P2X Receptor Antagonists/ or Estrogen Receptor Antagonists/ or Receptor-Like Protein Tyrosine Phosphatases, Clas 4/ or Serotonin 5-HT2 Receptor Antagonists/ or Receptor Cross-Talk/ or G-Protein-Coupled Receptor Kinase 2/ or Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/ or Angiotensin II Type 1 Receptor Blockers/ or Folate Receptor 2/ or Toll-like Receptor 10/ or Genes, T-Cell Receptor alpha/ or Receptor, Bradykinin B2/ or Interleukin-2 Receptor alpha Subunit/ or Bradykinin B2 Receptor Antagonists/ or Protein Tyrosine Phosphatase, Non-Receptor Type 4/ or Nuclear Receptor Kinases/ or Receptor Activity-Modifying Proteins/ or Protein Tyrosine Phosphatase, Non-Receptor Type 1/ or Cytokine Receptor Common beta Subunit/ or Interleukin-1 Receptor Accessory Protein/ or Transient Receptor Potential Channels/ or Retinoid X Receptor beta/ or Receptor, ErbB-4/ or G-Protein-Coupled Receptor Kinase 5/ or Receptor, Melanocortin, Type 1/ or Toll-Like Receptor 5/ or Purinergic P2Y Receptor Agonists/ or TNF Receptor 5/ or Puinergic P2Y Receptor Activity-Modifying Protein 3/ or Nuclear Receptor Subfamily 6, Group A, Member 1/ or Folate Receptor 1/ or Receptor, trkA/ or TNF Receptor-Associated Factor 1/ or Receptor, Melatonin, MT1/ or Adrenergic beta-2 Receptor Antagonists/ or Mineralocorticoid Receptor Antagonists/ or Serotonin 5-HT2 Receptor Agonists/ or Interleukin-15 Receptor alpha Subunit/ or Receptor, EphB2/ or Adenosine A2 Receptor Antagonists/ or Receptor Tyrosine Kinase-like Orphan Receptors/ or Purinergic P2 Receptor Agonists/ or Adrenergic alpha-2 Receptor Antagonists/ or NK Cell Lectin-Like Receptor Subfamily B/ or "Coxsackie and Adenovirus Receptor-Like Membrane Protein"/ or Adenosine A3 Receptor Agonists/ or Cannabinoid Receptor Antagonists/ or Receptor, Angiotensin, Type 2/ or Receptor, Fibroblast Growth Factor, Type 4/ or Receptor, Serotonin, 5-HT2C/
7. Tumor Marker$.mp or Biological/ or Adenocarcinoma/ or Drug Resistance.mp. Neoplasm/[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rate disease supplementary concept word, unique identifier]
8. Epidermal Growth Factor/ or EFGR.mp.
9. IGF Type 2/ or IGF Type 1/ or IGF$.mp.
10. RANK$.mp. or RANK Ligand/
11. Abdomen/ or Stomach/ or abdomen$.mp. or stoma$.mp.
12. A1B5$.mp.
13. Vascular Cell Adhesion Molecule-1/ or antigen$.mp.
14. CD/ or CD?105$.mp. or CD40 Ligand/ or CD40/ or CD?40$.mp.
15. Angiopoietin-2/ or Angiopoietin-1/ or angiopoietin$.mp. or ANG?2$.mp.
16. ErbB-2/ or Stomach Neoplasms/ or HER?2$.mp.
17. Desmosomal Cadherins/ or Cadherins/ or Cadherin$.mp.
18. Tumor Suppressor Protein p53/ or Gene$.mp. or P?53.mp.[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
19. (Adenovir$ or AD?5$).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
20. cetuxi$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
21. ramuci$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
22. figitu$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
23. denosum$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
24. CP?893.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
25. TR?105.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
26. CVX?241.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
27. pertuz$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
28. Antibod$.mp. or Monoclonal/ or Monoclon$.mp.
29. erbitux$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
30. Antineoplastic agents/ or Antineoplastic Combine Chemotherapy Protocols/ or antineoplas$.mp.
31. MLN?1202.mp.
32. Biological markers/ or C-Reactive Protein/
33. CP?752.mp.
34. CP?871.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
35. AMG?162.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
36. prolia$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
37. xgeva.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
38. "Drug-related side effects and Adverse Reactions"/ or adverse event.mp.
39. Anti-Inflammatory Agents/ or advers$.mp.
40. complication$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
41. meta-analysis.pt.
42. review.pt. and medline.tw.
43. 1 and 2
44. 3 or 4 or 28 or 30 or 32 or 39
45. 7 or 38 or 40
46. 41 or 42
47. 43 and 44 and 45 and 46
48. advers$.mp.
49. anti-inflammatory agents/ or anti?inflam$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
50. 1 or 11
51. 2 or 7
52. or/3-6
53. or/8-10
54. (or/13-37) or 12 or 49
55. or/52-54
56. 38 or 48 or 40
57. 41 or 42
58. 50 and 51 and 55 and 56 and 57


Total articles = 30

Notes


Recent changes



Personal tools